07:00 , Jul 21, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Gastrointestinal disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Gastrointestinal disease Bacterial infection; cholera; salmonella; gastrointestinal infection; diarrhea (infectious) Not applicable Mouse studies suggest retinoic acid could...
08:00 , Dec 13, 2010 |  BC Week In Review  |  Clinical News

ACE527: Phase II data

A double-blind, U.S. Phase II trial in 56 healthy volunteers showed that a 2-dose vaccination regimen with oral ACE527 missed the primary endpoint of significantly reducing the severity of diarrhea at 120 hours post-challenge with...
08:00 , Feb 1, 2010 |  BC Week In Review  |  Clinical News

ACE527: Phase I data

In a double-blind, placebo-controlled, U.S. Phase I trial in 36 healthy volunteers, ACE527 was well tolerated and induced a mucosal immune response to colonization factors on all 3 strains of E. coli included in the...
07:00 , Jun 23, 2008 |  BC Week In Review  |  Company News

Ace BioSciences, Program for Appropriate Technology in Health infectious news

Ace will receive $5 million over two years from the not-for-profit PATH to develop Ace’s ACE527 (formerly ACE537) vaccine to prevent diarrhea caused by enterotoxigenic Escherichia coli (ETEC). PATH will receive an exclusive...
07:00 , Mar 17, 2008 |  BC Week In Review  |  Company News

Ace BioSciences, Program for Appropriate Technology in Health deal

Ace and the not for profit partnered to develop temperature-stable formulation technologies for use in vaccines to treat diarrhea. The research will be funded by PATH. Both parties will have access to the resulting technologies....
07:00 , Jun 4, 2007 |  BC Week In Review  |  Company News

Ace BioSciences, Cambridge Biostability deal

Ace received an exclusive, worldwide license to Cambridge Biostability's HolaVax-ETEC vaccine, which will be renamed ACE537. The oral vaccine that comprises three strains of attenuated enterotoxigenic E. coli (ETEC) bacteria is in Phase...
07:00 , May 16, 2005 |  BC Week In Review  |  Company News

Acambis, Cambridge Biostability, Invitrogen deal

ACM granted Cambridge Biostability exclusive worldwide rights to an enterotoxigenic E. coli (ETEC) vaccine. ACM has completed four Phase I trials of a precursor to the HolaVax-ETEC vaccine. Cambridge plans to conduct trials of...
01:06 , May 11, 2005 |  BC Extra  |  Top Story

Acambis reports earnings

Acambis (LSE:ACM;ACAM) reported a first quarter 2005 loss per share of 4.1p, compared with a 1.2p loss in the same period in 2004. First quarter revenues were L6 million ($11.3 million), down 68% from L18.8...